UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

UBS expects investors to pay limited attention to GSK’s Q2 results, with attention shifting to an upcoming strategy update. The note implies near-term market reaction is likely muted unless the strategy update provides new guidance or trajectory changes.

Analysis

UBS expects investors to pay limited attention to GSK’s Q2 results, with attention shifting to an upcoming strategy update. The note implies near-term market reaction is likely muted unless the strategy update provides new guidance or trajectory changes.